Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewContinued efforts to translate diabetes cardiovascular outcome trials into clinical practicePeroxisomes and Kidney InjuryEffect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.Peroxisome Proliferator-Activated Receptor γ Regulates the Expression of Lipid Phosphate Phosphohydrolase 1 in Human Vascular Endothelial Cells.Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology.Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke-stimulated macrophagesRosiglitazone reduces blood pressure in female Dahl salt-sensitive ratsAngiotensin-(1-7) prevents diabetes-induced attenuation in PPAR-gamma and catalase activitiesDifferential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPARgamma gene.Maternal selenium status during early gestation and risk for preterm birthImpaired lipid metabolism in idiopathic pulmonary alveolar proteinosis.HO-1 Induced by Cilostazol Protects Against TNF-α-associated Cytotoxicity via a PPAR-γ-dependent Pathway in Human Endothelial CellsCardiac dysfunction in adipose triglyceride lipase deficiency: treatment with a PPARα agonist.peroxisome proliferator-activated receptor alpha activation-mediated regulation of endothelin-1 production via nitric oxide and protein kinase C signaling pathways in piglet cerebral microvascular endothelial cell culture.PPARs in alveolar macrophage biology.Pioglitazone treatment increases COX-2-derived prostacyclin production and reduces oxidative stress in hypertensive rats: role in vascular function.Genetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland.Peroxisome proliferator-activated receptor and age-related macular degenerationPPARgamma Agonists: Potential as Therapeutics for Neovascular RetinopathiesPeroxisome proliferator-activated receptors as molecular targets in relation to obesity and type 2 diabetes.Diabetes and hypertension: epidemiology of the relationship and pathophysiology of factors associated with these comorbid conditions.Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity.Oyster crude polysaccharides attenuates lipopolysaccharide-induced cytokines production and PPARγ expression in weanling piglets.PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cellsAntiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathwaysRat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma AgonistsPPARgamma and its ligands: therapeutic implications in cardiovascular disease.PPARalpha Ligands as Antitumorigenic and Antiangiogenic AgentsPPARγ and Its Role in Cardiovascular Diseases.Pioglitazone inhibits HIF-1α-dependent angiogenesis in rats by paracrine and direct effects on endothelial cellsPeroxisome proliferator-activated receptors and atherosclerosis.Mechanisms of cardiac radiation injury and potential preventive approaches.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α.Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.Antihypertensive effects of peroxisome proliferator-activated receptor-β/δ activation.Myocardial capillary density in normal and diabetic male rats: Effect of bezafibrate.Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation.
P2860
Q24561401-0B81016C-21BE-491C-AA6E-C16C39572E07Q26741860-BC2B5791-0EC8-470E-A71E-1EBAEBC2E2AEQ28595714-2857218E-8C80-4A8E-ADC9-B467C7700992Q33593476-2B4FD3A4-B930-4A7B-8C84-934BC4537069Q33738646-8733AB4D-F040-4566-A8F3-3FD98F77A40CQ33867982-02260B99-946D-4AF9-AF25-31730C81DDBDQ33916565-C483BABB-1B4C-4190-980F-63CDDB63CC91Q33937349-5A813197-B30F-4A20-B9E6-83940005672AQ34009599-B3C44F92-F32D-4F03-AB86-4B01FFB19E15Q34407931-BC25FB6B-1DEF-45CA-B796-7FA11E82BA85Q34584762-3D0233A4-8DEA-4F1B-9298-01020D363D1FQ34693303-CD7DD0EA-3668-4A69-BDB3-6B31BC684FF8Q34992980-8C88684E-9C88-4A21-800F-62648E802E05Q35014033-047EF93D-EED2-4DC6-B16C-8EE71EC2A3DEQ35708138-3141311D-98CD-44C9-BBEB-9F782853CCD8Q35853780-B4A56103-DD7A-4280-B13C-294FD78D0FD7Q36121727-44FD6033-CA5D-4251-BD10-502B08C6D875Q36159034-E228607C-DC13-4757-94BC-CFE5BCA663A3Q36445100-BDF68A93-8580-4223-B8D6-4937834933B2Q36446030-B3B87FC3-19FB-4D27-8F96-1F2BEB5DFCD2Q36676571-76BA3267-E2FF-442B-BDD5-D464C0B03C43Q36845108-63D7FA0D-A7E6-426B-8D73-8D5AEABD8B2FQ36904459-F6EACF65-2D73-4402-984A-051D961028B5Q36958256-9CCD912B-EBAE-45FC-933B-2333DE8385EDQ36985027-3D028095-7CBC-43FB-B511-316032C2E855Q37002797-93FE0412-E928-49E0-80AE-6D1997A07A25Q37033675-6E447366-778A-4253-A89A-A96E57E6B3C8Q37077098-696EA571-6930-450F-B3A5-3227CFC9A08CQ37179467-BD75E3F4-EBF3-4AFD-9E4E-9EFD445FC275Q37251719-052DD10E-9033-47C1-BB14-81CB3E6A863BQ37627571-AE7FE26E-00FD-4FFB-AEB6-973362058259Q37707352-14189E0A-E02F-400D-8778-DD2E87D754A4Q37861955-77BAD640-00C2-48F0-9260-EA1CAE5DF2FDQ38510734-16CA7B9B-B70D-4297-8437-2135B1F7BC99Q38674739-59F35C93-F8C7-4980-9593-406DFE39BC8CQ38674742-E2C79B6B-9E92-4878-9546-063CC0C7F981Q38824336-81604515-F20B-48D6-87FC-2CFFFC72AC7EQ39018398-24A11FBD-9BB6-4DC2-861C-E54B7C85C242Q42587472-46DECD1B-9F3C-44EF-A666-6684DEA0AC1DQ43042437-4C5E564A-6692-45B2-B404-DA17D6336A54
P2860
Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Peroxisome proliferator-activa ...... sms and clinical implications.
@ast
Peroxisome proliferator-activa ...... sms and clinical implications.
@en
type
label
Peroxisome proliferator-activa ...... sms and clinical implications.
@ast
Peroxisome proliferator-activa ...... sms and clinical implications.
@en
prefLabel
Peroxisome proliferator-activa ...... sms and clinical implications.
@ast
Peroxisome proliferator-activa ...... sms and clinical implications.
@en
P1476
Peroxisome proliferator-activa ...... sms and clinical implications.
@en
P2093
Ernesto L Schiffrin
Rhian M Touyz
P356
10.1016/J.VPH.2005.11.014
P577
2006-06-16T00:00:00Z